1
Clinical Trials associated with CISH inactivated tumor infiltrating lymphocyte cell therapy (Intima Bioscience)A Phase I/II Trial in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System
A clinical trial to assess the safety and efficacy of genetically-engineered, neoantigen-specific Tumor Infiltrating Lymphocytes (TIL) in which the intracellular immune checkpoint CISH has been inhibited using CRISPR gene editing for the treatment of Gastro-Intestinal (GI) Cancer.
100 Clinical Results associated with CISH inactivated tumor infiltrating lymphocyte cell therapy (Intima Bioscience)
100 Translational Medicine associated with CISH inactivated tumor infiltrating lymphocyte cell therapy (Intima Bioscience)
100 Patents (Medical) associated with CISH inactivated tumor infiltrating lymphocyte cell therapy (Intima Bioscience)
100 Deals associated with CISH inactivated tumor infiltrating lymphocyte cell therapy (Intima Bioscience)